Kytril and Urinary retention - a phase IV clinical study of FDA data

Summary:

Urinary retention is reported as a side effect among people who take Kytril (granisetron hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Urinary retention when taking Kytril. It is created by eHealthMe based on reports of 10,727 people who have side effects when taking Kytril from the FDA, and is updated regularly.

What is Kytril?

Kytril has active ingredients of granisetron hydrochloride. eHealthMe is studying from 10,766 Kytril users. Check the latest studies of Kytril.

What is Urinary retention?

Urinary retention (the inability to completely or partially empty the bladder) is found to be associated with 1,569 drugs and 1,738 conditions by eHealthMe. Check the latest studies of Urinary retention.

On Jul, 21, 2026

10,727 people reported to have side effects when taking Kytril.
Among them, 97 people (0.9%) have Urinary retention.

Among these 97 people:

How long have people been on Kytril when they have Urinary retention? *

What is the gender of people who have Urinary retention when taking Kytril? *

female: 41.94 %
male: 58.06 %

What is the age of people who have Urinary retention when taking Kytril? *

What are other drugs people take besides Kytril? *

What are other side effects people have besides Urinary retention? *

Anaemia (lack of blood): 40 people, 41.24%
Pain: 35 people, 36.08%
Constipation: 35 people, 36.08%
Osteonecrosis Of Jaw (death of bone of jaw): 35 people, 36.08%
Bone Disorder: 33 people, 34.02%
Stress And Anxiety: 31 people, 31.96%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 30 people, 30.93%
Fever: 30 people, 30.93%
Back Pain: 28 people, 28.87%
Injury: 27 people, 27.84%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 23 people, 23.71%
Breast Cancer: 22 people, 22.68%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 14 people, 14.43%
High Blood Pressure: 14 people, 14.43%
Pain: 14 people, 14.43%
Metastases To Bone (cancer spreads to bone): 8 people, 8.25%
Diabetes: 7 people, 7.22%
Lung Cancer Metastatic (lung cancer spreads to other parts): 6 people, 6.19%
Constipation: 6 people, 6.19%
Rectal Cancer (cancer of rectum): 6 people, 6.19%

* Approximation only. Some reports may have incomplete information.

Do you take Kytril and have Urinary retention?

- Check whether Urinary retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kytril:

Kytril (10,766 reports)

Browse all side effects of Kytril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary retention:

Urinary retention (1,569 drugs)

Browse all the conditions that are associated with Urinary retention:

Urinary retention (1,738 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on granisetron hydrochloride (the active ingredients of Kytril) and Kytril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.